Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event, Wrong product administered
Clinical narrative: No adverse reaction; The patient received a bivalent vaccine instead of the second series of her monovalent vaccine for a primary series; Greater than 35 days between primary series doses of the Moderna Covid-19 vaccine/ Received Bivalent vaccine as second dose; This spontaneous case was reported by a nurse and describes the occurrence of WRONG PRODUCT ADMINISTERED (The patient received a bivalent vaccine instead of the second series of her monovalent vaccine for a primary series), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between primary series doses of the Moderna Covid-19 vaccine/ Received Bivalent vaccine as second dose) and NO ADVERSE EVENT (No adverse reaction) in a 54-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS71468) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Sep-2022, the patient received second dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 27-Sep-2022, the patient experienced WRONG PRODUCT ADMINISTERED (The patient received a bivalent vaccine instead of the second series of her monovalent vaccine for a primary series) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between primary series doses of the Moderna Covid-19 vaccine/ Received Bivalent vaccine as second dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse reaction). At the time of the report, WRONG PRODUCT ADMINISTERED (The patient received a bivalent vaccine instead of the second series of her monovalent vaccine for a primary series), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between primary series doses of the Moderna Covid-19 vaccine/ Received Bivalent vaccine as second dose) and NO ADVERSE EVENT (No adverse reaction) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse reaction) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (The patient received a bivalent vaccine instead of the second series of her monovalent vaccine for a primary series) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between primary series doses of the Moderna Covid-19 vaccine/ Received Bivalent vaccine as second dose).    No concomitant medications were reported. No treatment medications were reported.  Patient's weight and height were unknown.  Patient received a first dose of the Moderna Monovalent vaccine in primary series and was due for second dose. The patient received a bivalent vaccine instead of the second series of monovalent vaccine for a primary series. Reporter asked how should we proceed with patient.  On 30-Dec-2021, the patient received first Moderna Covid-19 primary series vaccine (lot number 031H21A, expiration date was not provided, not known which arm). No adverse reactions were reported.  The patient did not report any adverse events following bivalent dose.